Partner Therapeutics, Inc.
Life Sciences Drug DevelopmentLexington, MA
Partner Therapeutics (PTx) is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products in support of medical teams with the purpose of creating the best possible outcomes for patients and their families. PTx announced on February 1, 2018 that it acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is a multi-lineage immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the only immune modulator approved by the FDA for the treatment of acute myelogenous leukemia (AML) in older patients and for use in both allogeneic and autologous bone marrow transplantation.